Skip to main contentSkip to navigationSkip to search
Curasight

Press releases

2023

Interim Report January – September 2023

November 23, 2023
 | Regulatory
Business Highlights during the third quarter 2023

· Encouraging preclinical data using uTREAT[®] in non-small cell lung cancer
· Positive Phase II data reported from uTRACE[®] in brain cancer
· Advancing the theranostics by ongoing momentum in development pipeline with data and regulatory progress 

Copenhagen, Denmark, 23 November 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report for the period January 1 – September 30, 2023. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Curasight A/S reports positive preclinical results with uTREAT[®] in lung cancer (NSCLC)

October 18, 2023
 | Regulatory

· Preclinical studies show uTREAT[®] effective in treating non-small cell lung cancer (NSCLC)

· Data follows recent announcement of positive preclinical results within glioblastoma and supports hypothesis that uTREAT[®] has treatment potential in additional solid tumors

· Data highlights potential of company’s uPAR theranostic platform to combine diagnosis (uTRACE[®]) with more gentle and targeted treatment (uTREAT[®])

Copenhagen, October 18, 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) is pleased to announce preclinical data demonstrating preclinical proof of concept of uTREAT[®] in treating non-small cell lung cancer (NSCLC). Today’s news follows the announcement earlier this year of positive preclinical results of uTREAT[®] in glioblastoma.

Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

September 14, 2023
 | Regulatory
Oral presentation gives more details from the Phase II data where topline results were released on June 29, 2023.

Investigators for the Phase II trial concluded that:

· The majority of the glioma patients displayed uPAR-positive tumors
· High uPAR expression is significantly correlated with a worse outcome
· The study demonstrates the potential of uPAR-targeted radionuclide therapy (uTREAT®) for patients with high-grade gliomas

Copenhagen, Denmark, September 14, 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today that the previously announced results from the investigator-initiated phase II study using uPAR-PET (uTRACE®) in primary brain cancer have been presented in an oral presentation at the World Molecular Imaging Congress (WMIC) 2023 in Prague.

Curasight to present at HC Andersen Capital and at HC Andersen Life Science seminar

August 25, 2023
 | Regulatory
Copenhagen, Denmark, 25 August 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company’s Interim Report Q2 2023 at HC Andersen Capital 30 August and the clinical progress at HC Andersen Capital Life Science seminar, 31 August 2023. 

Interim Report January – June 2023

August 24, 2023
 | Regulatory
Copenhagen, Denmark, 24 August 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report for the period January 1 – June 30, 2023. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Positive results in uPAR-PET/MR Phase II study in brain cancer

June 29, 2023
 | Regulatory

· uPAR-PET with [68]Ga-NOTA-AE105 (now known as uTRACE[®]) was highly prognostic both regarding progression-free survival and overall survival.
· 94% of glioblastomas (WHO grade 4 gliomas) in the study were uPAR-PET positive underlines validity of using this target for improved diagnosis and categorisation.
· Together with our recently reported positive preclinical data on therapy with uTREAT[®] in glioblastoma, this strongly supports our ambition to pursue a theranostic approach using uTRACE[®] and uTREAT[®] in glioblastoma patients.

Copenhagen, Denmark, June 29, 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today positive results from the investigator-initiated phase II study using uPAR-PET (uTRACE[®]) in primary brain cancer. The study found that uPAR-PET/MR was a suitable target for the detection and prognosis of primary glioblastomas, the most common type of primary brain cancer.

Curasight A/S reports positive preclinical results with uTREAT[®] in aggressive brain cancer (glioblastoma)

June 7, 2023
 | Regulatory

· Preclinical studies show uTREAT[®] efffective in treating aggressive brain cancer
· Data supports strategy to move uTREAT[®] into clinical development for evaluation in patients with aggressive brain cancer

Copenhagen, June 7, 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) is pleased to announce preclinical data demonstrating the effectiveness of uTREAT[®] in treating aggressive brain cancer (glioblastoma). The results from the study validate Curasight's strategic focus on developing uTREAT[®] as a viable treatment option for patients with aggressive brain cancer.

Curasight to present at HC Andersen Capital and Økonomisk Ugebrev

May 26, 2023
 | Regulatory
Copenhagen, Denmark, 26 May 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company’s Interim Report Q1 2023 at HC Andersen Capital and at Økonomisk Ugebrev, 31 May 2023.  

Interim report Q1 2023

May 25, 2023
 | Regulatory
Copenhagen, Denmark, 25 May 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report Q1 2023. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Curasight and Curium announce global partnership for uTRACE[®] in prostate cancer

May 1, 2023
 | Regulatory

· Curasight to develop its proprietary uTRACE[®] PET imaging technology to obtain regulatory approval in EU and USA, with Curium responsible for manufacturing and commercialization
· Curasight eligible for up to USD 70 mn in development and commercial milestones as well as double-digit royalties on sales on eventual commercialization
· The agreement supports Curasight’s strategy to leverage partnerships as it progresses its uPAR theranostic solution to diagnose and treat certain types of cancer
Load more